10
May
2023
|
09:59 AM
Europe/Amsterdam
Not intended for U.S. and UK Media
Summary
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) / QUASAR is expected to enroll around 800 patients in 27 countries / Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual acuity with extended treatment intervals in additional patient populations
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here